Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 8 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Mar. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating Activities:              
Net loss $ (205) $ (486) $ (242) $ (828) $ (10,583) $ (1,234) $ (828)
Adjustments to reconcile net loss to net cash used in operating activities:              
Gain on warrants [note 8 and note 12[e]]         (150)    
Depreciation         59    
Amortization         223 223 140
Stock-based compensation [note12[c]]         348    
Deferred income tax (recovery) (124) (127) (118) (407) (3,051) (504) (407)
Bargain purchase gain         (1,272)    
Loss on disposition         8,610    
Contingent value rights recovery         (200)    
Changes in operating assets and liabilities:              
Amounts receivable         (9)    
Prepaid expenses and other assets         (1,349) (2)  
Accounts payable         118 22 57
Accrued liabilities other         (2,185) 670 284
Accrued clinical liabilities         877    
Accrued compensation         458    
Salaries payable         (1,028) 623 404
Lease obligation         27    
Net cash used in operating activities         (9,107) (202) (350)
Financing Activities:              
Proceeds from share subscription         64    
Taxes paid related to net share settlement of equity awards         (5)    
Payments on loan             (272)
Stockholder loans           150 2,683
Net cash provided by financing activities         2,001 150 2,411
Investing Activities:              
Cash received on reverse takeover of OncoGenex         12,648    
Purchase of Extab Corporation common stock [note 6]             (2,000)
Net cash provided by (used in) investing activities         12,648   (2,000)
Effect of exchange rate changes on cash         (1)    
Net increase (decrease) in cash, cash equivalents and restricted cash         5,541 (52) 61
Cash, cash equivalents and restricted cash at beginning of year $ 15   $ 67   15 67 6
Cash, cash equivalents and restricted cash at end of year   $ 15   $ 67 5,556 15 67
Supplemental Disclosure of Cash Flow Information:              
Interest expense accrued but not yet paid           $ 26 $ 11
ATM Financing              
Financing Activities:              
Proceeds from ATM Financing, net of issuance costs         $ 1,942